The Breast Oncology Center at the Susan F. Smith Center for Women's Cancers at Dana-Farber provides state-of-the-art and compassionate care for breast cancer patients. Our breast cancer clinicians are committed to providing your patients with the best and most individualized treatment options available, including the latest medical oncology, surgical options, breast reconstruction, and radiation therapy.
Our focused and specialized services include programs for: young adults with breast cancer, metastatic breast cancer, inflammatory breast cancer, breast cancer during pregnancy, breast and ovarian cancer genetics and prevention, older adults with breast cancer, patients with breast cancer brain metastases, breast cancer in men, and ductal carcinoma in situ (DCIS).
View Treatment Guidelines and Other ResourcesFeatured Content |view more
Symposium
San Antonio Breast Cancer Symposium 2025
Many Dana-Farber clinician scientists are participating in the 2025 San Antonio Breast Cancer Symposium (SABCS), held December 9-12 in San Antonio Texas.
Symposium
Review video summaries and research highlights from Dana-Farber Faculty, presented at ESMO Congress 2025.
Document
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of ovarian function suppression and estradiol monitoring in early-stage estrogen receptor positive breast cancer.
News
Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan ...
News
Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective ...
News
Breast, Lung, and Bladder Cancer Phase 3 Trials led by Dana-Farber Presented at ESMO Congress 2025
Dana-Farber Cancer Institute researchers are leading four studies with important new findings in breast cancer, lung cancer, and bladder cancer at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany.
